COST-EFFECTIVENESS ANALYSIS OF ADJUVANT OSIMERTINIB IN RESECTED EGFR-MUTATED EARLY-STAGE NON-SMALL CELL LUNG CANCER IN THAILAND. ICOPH 2025, 9 (1), 45-67. https://doi.org/10.17501/24246735.2024.9105.